• Patent Title: Screening assay for identifying miRNA-specific drug compounds
  • Application No.: US15316488
    Application Date: 2015-06-02
  • Publication No.: US11021761B2
    Publication Date: 2021-06-01
  • Inventor: Yaakov BenensonBenjamin Hafliger
  • Applicant: ETH ZURICH
  • Applicant Address: CH Zurich
  • Assignee: ETH ZURICH
  • Current Assignee: ETH ZURICH
  • Current Assignee Address: CH Zurich
  • Agency: Cantor Colburn LLP
  • Agent Bryan D. Zerhusen, Esq.; Nicholas R. Herrel, Esq.
  • Priority: EP14001958 20140605
  • International Application: PCT/EP2015/062258 WO 20150602
  • International Announcement: WO2015/185551 WO 20151210
  • Main IPC: C12Q1/6897
  • IPC: C12Q1/6897
Screening assay for identifying miRNA-specific drug compounds
Abstract:
The present invention relates to a method for identifying miRNA (microRNA)-modulating compounds by contacting a compound of interest with a cell comprising (i) a “miRNA-specific module” that reports specific miRNA target sequence binding by means of a first reporter product; (ii) a “non-specific RNAi module” that reports altered expression of one or more endogenous miRNAs with baseline expression levels in the cell (“non-specific miRNA markers”) by means of a second reporter product; and optionally (iii) a “gene expression module” that reports global changes in gene expression; and subsequent detection of changes in reporter product expression. The advantage of this method is that non-specific miRNA- and/or RNAi-effects of the compound of interest are detected and false positive results due to the structural similarity of different miRNAs and the commonly shared maturation pathway for most miRNAs are substantially reduced over conventional miRNA screening assays.
Public/Granted literature
Information query
Patent Agency Ranking
0/0